Chimeric antigen receptor T cell therapy: 25years in the making.
about
Clinical manufacturing of CAR T cells: foundation of a promising therapyChimeric antigen receptor T-cell therapy for solid tumorsImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.Autologous lymphapheresis for the production of chimeric antigen receptor T cells.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsCSPG4: a prototype oncoantigen for translational immunotherapy studies.Masked Chimeric Antigen Receptor for Tumor-Specific Activation.Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors.Immunotherapy for Esophageal Squamous Cell Carcinoma.Bioengineering solutions for manufacturing challenges in CAR T cells.Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Cloning and molecular characterization of the cDNAs encoding the variable regions of an anti-CD20 monoclonal antibody.Current status of engineered T-cell therapy for synovial sarcoma.Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelAn ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors.Driving an improved CAR for cancer immunotherapy.Anticancer cellular immunotherapies derived from umbilical cord blood.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models.Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.Mechanisms regulating T-cell infiltration and activity in solid tumors.Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Genetically enhanced T lymphocytes and the intensive care unit.Nephrotoxicity of Cancer Immunotherapies: Past, Present and FutureThe application of CAR-T cell therapy in hematological malignancies: advantages and challenges
P2860
Q26747037-2B880071-1CFD-4CA7-BB4C-5493F3C50671Q26750908-F7C5F63D-3872-471D-B22B-C8D3914D0495Q28078539-D1BEFFF9-CE80-4582-9466-943FD7E7F7C5Q30251555-A869D3EF-5B8B-423B-BE39-72F00D774D7FQ30253090-73C3B4B9-0F5D-443A-A315-8557543BBA21Q33833475-66254BE7-02E0-4BB5-8A13-ABADF638A480Q33862585-DAE6198F-494A-47A9-B937-26821945A5F3Q34047878-BE2398F9-ACB6-4EEE-B102-CC423BF2CE4FQ37481319-AEDFCE68-9B35-4101-B2AE-683083580278Q37730966-166C3AB4-23AB-4A39-A0F6-BB7EEB12C705Q38637370-68AA570E-F76F-47BF-8B7B-B03594700270Q38685785-41F514E0-4933-4FBF-B77E-ECA253CAFDD4Q38713259-E9ED0D31-48C5-4B45-ADD5-804FA3C755B1Q38916522-52499225-17D6-494A-992F-1155355594E3Q38916529-36F1C796-5E81-4ED9-8620-61BE8E1C19B5Q39039017-E9873CF5-A574-4C73-A13E-700B17807B08Q39194733-0BEEE482-FDFD-44A6-AF6B-3E2494B00848Q39249589-775DE474-C4C9-4729-806F-DB65E2F9EC9EQ41252003-CFB42CC2-C19A-457D-82C9-A71682E572C7Q41844141-2AE45122-2512-4165-A2C7-8C8516FC9E3CQ47657491-5B66F781-EA5B-4A90-B2CC-91CA6BF8158BQ49315568-30B33620-5474-4456-85C1-D781D865D376Q49477144-A7A7D7C9-9578-4D2F-B6F3-754B75AC5301Q50025585-C10B846B-9C50-43CB-AC7F-92B4CA0A65CDQ50028184-D6ACAA14-35D2-4126-8619-61C5EA0C08AFQ50089395-4AA0C21D-4599-4C4B-8759-E9B6112244D3Q52663662-73B9E13C-6B83-4730-B520-FE64C7EAE92AQ54378300-C2133248-EFC5-487E-9019-94748320C7C5Q55380614-63E0E13D-76B3-4F4D-9D29-FD87E9E5D8C8Q57172529-443734DD-FFBC-4761-9A8C-BA6D9BA5CD83Q57177485-639FF594-292E-409B-9336-1B889DD34488
P2860
Chimeric antigen receptor T cell therapy: 25years in the making.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Chimeric antigen receptor T cell therapy: 25years in the making.
@en
type
label
Chimeric antigen receptor T cell therapy: 25years in the making.
@en
prefLabel
Chimeric antigen receptor T cell therapy: 25years in the making.
@en
P1433
P1476
Chimeric antigen receptor T cell therapy: 25years in the making.
@en
P2093
David L Porter
P304
P356
10.1016/J.BLRE.2015.10.003
P577
2015-11-06T00:00:00Z